


S Table1 Clinical features of including patients


	Neuroendocrine carcinoma (%)	Squamous cell carcinoma (%)	Adenocarcinoma (%)	P-value
Median survival (month)	7.81	9.24	11.19	
Gender				<0.01
Female	71 (28.86)	1972 (32.32)	1534 (14.14)	
Male	175 (71.14)	4130 (67.68)	9314 (85.86)	
Age				
Mean age	66.65	67.19	66.10	
<66 year-old	117 (47.56)	2807 (46.00)	5418 (49.94)	
>=66 year-old	129 (52.44)	3295 (54.00)	5430 (50.06)	
Location				<0.01
Upper third of esophagus	13 (5.28)	976 (15.99)	125 (1.15)	
Middle third of esophagus	61 (24.80)	2365 (38.76)	870 (8.02)	
Lower third of esophagus	130 (52.85)	1779 (29.15)	8435 (77.76)	
Unspecific	42 (17.07)	982 (16.09)	1418 (13.07)	
Grade				<0.01
I	1 (0.41)	195 (3.20)	379 (3.49)	
II	2 (0.81)	2252 (36.91)	3487 (32.14)	
III	125 (50.81)	2453 (40.20)	5141 (47.39)	
IV	50 (20.33)	47 (0.77)	136 (1.25)	
Unspecific	68 (27.64)	1155 (18.93)	1705 (15.72)	
Tumorsize				<0.01
<2cm	15 (6.10)	312 (5.11)	666 (6.14)	

	2-3cm	9 (3.66)	416 (6.82)	727 (6.70)	
	3-4cm	16 (6.50)	515 (8.44)	878 (8.09)	
	4-5cm	14 (5.69)	601 (9.85)	1024 (9.44)	
	5-6cm	19 (7.72)	453 (7.42)	670 (6.18)	
	6-7cm	22 (8.94)	291 (4.77)	483 (4.45)	
	7-8cm	10 (4.07)	263 (4.31)	392 (3.61)	
	>8cm	28 (11.38)	501 (8.21)	726 (6.69)	
	Unspecific	113 (45.93)	2750 (45.07)	5282 (48.69)	
Tstage					<0.01
	T0	0 (0.00)	4 (0.07)	5 (0.05)	
	T1	62 (25.20)	1561 (25.58)	2530 (23.32)	
	T2	12 (4.88)	380 (6.23)	838 (7.72)	
	T3	36 (14.63)	1335 (21.88)	3075 (28.35)	
	T4	50 (20.33)	1227 (20.11)	1439 (13.27)	
	Unspecific	86 (34.96)	1595 (26.14)	2961 (27.30)	
Nstage					<0.01
	N0	74 (30.08)	2305 (37.77)	3621 (33.38)	
	N1	114 (46.34)	2689 (44.07)	5113 (47.13)	
	N2	4 (1.63)	197 (3.23)	409 (3.77)	
	Unspecific	54 (21.95)	911 (14.93)	1705 (15.72)	
Mstage					<0.01
	M0	80 (32.52)	3583 (58.72)	5062 (46.66)	
	M1	153 (62.20)	2147 (35.19)	5313 (48.98)	
	Unspecific	13 (5.28)	372 (6.10)	473 (4.36)	
Metastasis site					<0.01

Liver	45 (29.41)	313 (14.58)	1228 (23.11)	
Lung	14 (9.15)	340 (15.84)	575 (10.82)	
Brain	5 (3.27)	24 (1.12)	161 (3.03)	
Bone	15 (9.80)	209 (9.73)	561 (10.56)	
Distant lymph nodes	19 (12.42)	330 (15.37)	702 (13.21)	
Primary site surgery				<0.01
Yes	15 (6.10)	625 (10.24)	2116 (19.51)	
No	231 (93.9)	5477 (89.76)	8732 (80.49)	
Lymph node dissection				<0.01
Yes	10 (4.07)	570 (9.34)	1979 (18.24)	
No	236 (95.93)	5532 (90.66)	8869 (81.76)	
Distant metastasis sites dissection				<0.01
Yes	0 (0)	4 (0.07)	12 (0.11)	
No	246 (100.00)	6098 (99.93)	10836 (99.89)	



Supplementary Figure 1: Flow chart depicting the selection of patients.



Supplementary Figure 2: The prevalence of three main kinds of esophageal cancer during 2004-2014.

*: The percentage in the Y-axis represents the proportion of three esophageal cancer and the percentage in the graph represents the prevalence of each cancer.